Fusilev FDA Approval History
FDA Approved: Yes (First approved March 7, 2008)
Brand name: Fusilev
Generic name: levoleucovorin
Dosage form: for Injection
Company: Spectrum Pharmaceuticals, Inc.
Treatment for: Methotrexate Rescue, Folic Acid Antagonist Overdose, Colorectal Cancer
Fusilev (levoleucovorin calcium) is a folate analog indicated for rescue after high-dose methotrexate therapy in osteosarcoma, diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists, and for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.
Development Timeline for Fusilev
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.